- Exchange: NASDAQ GM
- Sector: Consumer, Non-cyclical
- Industry: Pharmaceuticals
- Sub-Industry: Therapeutics
Osiris Therapeutics Inc
+ Add to WatchlistOSIR:US
11.2700 USD 0.6700 6.32%As of 20:10:00 ET on 05/17/2013.
Snapshot for Osiris Therapeutics Inc (OSIR)
| Open: | 10.6000 | Day's Range: | 10.4200 - 11.3900 | Volume: | 175,051 |
|---|---|---|---|---|---|
| Previous Close: | 10.6000 | 52wk Range: | 5.5100 - 14.4600 | 1-Yr Rtn: | +103.06% |
Key Statistics for OSIR
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. SPX | - |
| Earnings Per Share (USD) (ttm) | -0.3800 |
| Est. EPS (USD) (12/2013) | -0.3050 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 371.14 |
| Shares Outstanding (M) | 32.93 |
| 30 Day Average Volume | 108,131 |
| Price/Book (mrq) | 10.9728 |
| Price/Sale (ttm) | 32.3350 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 07/30/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for OSIR
Company Profile & Key Executives for OSIR
Osiris Therapeutics, Inc. researches and develops therapeutic products for the regeneration of human connective tissues. The Company is focusing its initial product development efforts on the regeneration of bone marrow stroma following high-dose cancer chemotherapy, and on the regeneration of bone in long bone and spinal defects.
| Charles Randal MillsPresident/CEO | Philip R Jacoby JrCFO/Treasurer/Secretary |
| Lode DebrabandereChief Operating Officer | Michelle Leroux WilliamsChief Scientific Officer |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
OSIR News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page